Zomedica Corp. (ZOMDF) stock
ZOMDFOTCPharmaceutical PreparationsFiscal year ends December 31
$0.08−0.00 (-0.55%)
Close on Oct 19, 2026Market cap $77.40MP/E –Yield –
Zomedica gross margin
Gross margin is gross profit as a percentage of revenue.
Zomedica's gross margin for the twelve months ending Sep 30, 2026 was 64.0%. For fiscal 2025 it was 67.7%, against 70.0% the year before. The highest annual figure on record is 73.9% in fiscal 2021.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 67.7% | −2.3 |
| FY2024 | Dec 31, 2024 | 70.0% | +1.2 |
| FY2023 | Dec 31, 2023 | 68.8% | −2.4 |
| FY2022 | Dec 31, 2022 | 71.1% | −2.7 |
| FY2021 | Dec 31, 2021 | 73.9% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | 61.1% | −6.1 |
| Q2 FY2026 | Jun 30, 2026 | 63.5% | −3.5 |
| Q1 FY2026 | Mar 31, 2026 | 62.3% | −5.5 |
| Q4 FY2025 | Dec 31, 2025 | 68.5% | −1.8 |
| Q3 FY2025 | Sep 30, 2025 | 67.2% | −5.2 |
| Q2 FY2025 | Jun 30, 2025 | 67.0% | −4.1 |
| Q1 FY2025 | Mar 31, 2025 | 67.8% | +2.1 |
| Q4 FY2024 | Dec 31, 2024 | 70.3% | +1.1 |
| Q3 FY2024 | Sep 30, 2024 | 72.3% | +3.6 |
| Q2 FY2024 | Jun 30, 2024 | 71.1% | +3.9 |
| Q1 FY2024 | Mar 31, 2024 | 65.7% | −4.2 |
| Q4 FY2023 | Dec 31, 2023 | 69.1% | +0.7 |
| Q3 FY2023 | Sep 30, 2023 | 68.7% | −4.8 |
| Q2 FY2023 | Jun 30, 2023 | 67.2% | −3.6 |
| Q1 FY2023 | Mar 31, 2023 | 70.0% | −3.1 |
| Q4 FY2022 | Dec 31, 2022 | 68.4% | −6.6 |
| Q3 FY2022 | Sep 30, 2022 | 73.5% | +51.8 |
| Q2 FY2022 | Jun 30, 2022 | 70.8% | +195.8 |
| Q1 FY2022 | Mar 31, 2022 | 73.0% | +15.9 |
| Q4 FY2021 | Dec 31, 2021 | 75.0% | – |
| Q3 FY2021 | Sep 30, 2021 | 21.7% | – |
| Q2 FY2021 | Jun 30, 2021 | -125.0% | – |
| Q1 FY2021 | Mar 31, 2021 | 57.1% | – |
See a number that looks wrong?